Cardiovascular effects of GLP-1 receptor agonists: atherosclerotic outcomes, obesity, HFpEF, and kidney disease — a narrative review.
Introduction and Objective. Cardiovascular disease (CVD) is a major cause of morbidity and mortality, especially in type 2 diabetes mellitus (T2DM). Selected glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular benefit beyond glucose lowering. The aim of the review is to summarize compound-specif...